
  
    
      
        Background_NNP
        The_DT mitogen-activated_JJ protein_NN kinase_NN (_( MAPK_NNP )_) family_NN
        consists_VBZ of_IN three_CD commonly_RB recognized_VBN subgroups_NNS :_: the_DT
        extracellular_NN signal-regulated_JJ kinase_NN (_( ERK_NNP )_) ,_, the_DT
        c-jun-_JJ N-_NNP terminal_NN kinase_NN (_( JNK_NNP )_) ,_, also_RB known_VBN as_IN the_DT stress_NN
        activated_VBN protein_NN kinase_NN (_( SAPK_NNP )_) and_CC the_DT p_NN 38_CD kinase_NN ._. While_IN
        many_JJ actions_NNS have_VBP been_VBN associated_VBN with_IN activation_NN of_IN the_DT
        ERK_NNP pathway_NN ,_, two_CD particular_JJ functions_NNS of_IN interest_NN to_TO our_PRP$
        laboratory_NN are_VBP mitogen-stimulated_JJ growth_NN [_NN 1_CD ]_NN and_CC smooth_JJ
        muscle_NN cell_NN contraction_NN [_NN 2_CD ]_NN ._. Of_IN the_DT three_CD MAPK_NNP pathways_NNS ,_,
        activation_NN of_IN the_DT ERK_NNP pathway_NN and_CC the_DT intracellular_NN
        signaling_VBG pathways_NNS associated_VBN with_IN ERK_NNP activation_NN are_VBP the_DT
        best_JJS delineated_JJ ._. Known_VBN activators_NNS include_VBP reactive_JJ oxygen_NN
        species_NNS [_NN 3_CD 4_CD ]_NN ,_, growth_NN factors_NNS [_NN 5_CD ]_NN ,_, and_CC agonists_NNS of_IN
        G-_NNP protein_NN coupled_VBN receptors_NNS [_NN 6_CD 7_CD ]_NN ._. The_DT two_CD other_JJ MAPK_NNP
        pathways_NNS ,_, the_DT JNK_NNP and_CC p_NN 38_CD pathways_NNS ,_, have_VBP been_VBN implicated_VBN in_IN
        a_DT variety_NN of_IN similar_JJ cellular_JJ functions_NNS ._. Known_VBN activators_NNS
        of_IN the_DT JNK_NNP and_CC p_NN 38_CD pathways_NNS in_IN vascular_NN smooth_JJ muscle_NN cells_NNS
        include_VBP reactive_JJ oxygen_NN species_NNS [_NN 8_CD 9_CD ]_NN ,_, mechanical_JJ strain_NN
        [_NN 10_CD 11_CD ]_NN ,_, hypoxia_NN [_NN 12_CD ]_NN and_CC a_DT variety_NN of_IN cytokines_NNS and_CC
        growth_NN factors_NNS ._. The_DT mechanisms_NNS of_IN many_JJ cellular_JJ functions_NNS
        of_IN the_DT JNK_NNP and_CC p_NN 38_CD pathways_NNS are_VBP not_RB yet_RB clearly_RB defined_VBN ._.
        The_DT JNK_NNP pathway_NN is_VBZ involved_VBN in_IN apoptosis_NNS [_NN 13_CD ]_NN ,_, arginine_NN
        vasopressin-induced_JJ increases_NNS in_IN smooth_JJ muscle_NN α-actin_JJ in_IN
        vascular_NN smooth_JJ muscle_NN cells_NNS [_NN 14_CD ]_NN as_RB well_RB as_IN in_IN
        phosphorylation_NN of_IN transcription_NN factors_NNS c-jun_JJ ,_, ATF-_NNP 2_CD and_CC
        ELK-_NNP 1_CD and_CC phosphorylation_NN of_IN Na-_NNP K-_NNP 2_CD CI_NNP cotransporter_NN [_NN 15_CD ]_NN
        ._. The_DT p_NN 38_CD pathway_NN has_VBZ been_VBN implicated_VBN in_IN apoptosis_NNS [_NN 16_CD ]_NN ,_,
        neointimal_NN hyperplasia_NN after_IN vascular_NN injury_NN [_NN 17_CD ]_NN as_RB well_RB
        as_IN angiotensin_NN ll-induced_JJ contraction_NN in_IN vascular_NN smooth_JJ
        muscle_NN [_NN 18_CD ]_NN ._.
        Recently_RB ,_, it_PRP has_VBZ been_VBN noted_VBN that_IN the_DT JNK_NNP and_CC p_NN 38_CD
        pathways_NNS can_MD be_VB activated_VBN by_IN G-_NNP protein_NN coupled_VBN receptor_NN
        agonists_NNS ,_, notably_RB angiotensin_NN II_NNP ,_, in_IN vascular_NN smooth_JJ muscle_NN
        cells_NNS [_NN 19_CD 20_CD ]_NN ._. In_IN cardiac_JJ myocytes_NNS ,_, both_DT the_DT p_NN 38_CD and_CC JNK_NNP
        pathways_NNS have_VBP been_VBN activated_VBN by_IN endothelin-_NN 1_CD (_( ET-_NNP 1_LS )_) and_CC the_DT
        α_NN 
        1_CD adrenergic_JJ receptor_NN agonist_NN
        phenylephrine_NN [_NN 21_CD ]_NN ._. The_DT ability_NN of_IN the_DT JNK_NNP and_CC p_NN 38_CD
        pathways_NNS to_TO be_VB activated_VBN by_IN the_DT same_JJ agonists_NNS of_IN G-_NNP protein_NN
        coupled_VBN receptors_NNS which_WDT activate_VBP the_DT ERK_NNP pathway_NN led_VBN to_TO the_DT
        investigation_NN of_IN 5_CD -_: HT_NNP as_IN a_DT possible_JJ activator_NN of_IN the_DT JNK_NNP
        and_CC p_NN 38_CD pathways_NNS ._. 5_LS -_: HT_NNP ,_, acting_VBG 
        via_IN the_DT 5_CD -_: HT_NNP 
        2_CD A_DT receptor_NN ,_, is_VBZ a_DT known_VBN activator_NN of_IN the_DT
        ERK_NNP pathway_NN in_IN vascular_NN smooth_JJ muscle_NN cells_NNS [_NN 2_CD 22_CD ]_NN ._. In_IN
        these_DT studies_NNS we_PRP tested_VBD the_DT hypothesis_NNS that_IN 5_CD -_: HT_NNP would_MD
        activate_VBP the_DT JNK_NNP and_CC p_NN 38_CD pathways_NNS in_IN rat_NN aortic_JJ vascular_NN
        smooth_JJ muscle_NN cells_NNS ._.
      
      
        Results_NNS
        
          The_DT ERK_NNP pathway_NN
          In_IN agreement_NN with_IN previously_RB published_VBN studies_NNS from_IN
          our_PRP$ lab_NN ,_, 5_CD -_: HT_NNP caused_VBD a_DT concentration-dependent_JJ activation_NN
          of_IN the_DT ERK_NNP pathway_NN (_( figure_NN 1_LS )_) ._. This_DT activation_NN occurs_VBZ
          maximally_RB at_IN five_CD minutes_NNS of_IN stimulation_NN and_CC returns_NNS to_TO
          basal_NN levels_NNS by_IN thirty_CD minutes_NNS [_NN 23_CD ]_NN ._. This_DT time_NN course_NN
          of_IN activation_NN is_VBZ consistent_JJ with_IN that_DT of_IN other_JJ G-_NNP protein_NN
          coupled_VBN receptors_NNS ._.
        
        
          The_DT p_NN 38_CD pathway_NN
          The_DT p_NN 38_CD pathway_NN has_VBZ demonstrated_VBN a_DT different_JJ time_NN
          course_NN of_IN activation_NN 
          via_IN G-_NNP protein_NN coupled_VBN receptors_NNS
          than_IN the_DT ERK_NNP pathway_NN [_NN 24_CD ]_NN ._. Using_VBG the_DT time_NN point_NN (_( 30_CD
          min_NN )_) at_IN which_WDT angiotensin_NN II_NNP demonstrates_VBZ maximal_NN
          stimulation_NN of_IN the_DT JNK_NNP pathway_NN we_PRP performed_VBD a_DT
          concentration_NN response_NN curve_NN (_( 10_CD -_: 9_CD -_: 10_CD -_: 5_CD M_NNP )_) to_TO 5_CD -_: HT_NNP in_IN
          vascular_NN smooth_JJ muscle_NN cells_NNS ._. Western_JJ analysis_NN using_VBG
          phosphospecific_JJ antibodies_NNS was_VBD used_VBN to_TO measure_VB activation_NN
          the_DT p_NN 38_CD pathway_NN ._. A_DT total_JJ or_CC non-phosphospecific_JJ antibody_NN
          was_VBD used_VBN to_TO ensure_VB equal_JJ loading_NN of_IN p_NN 38_CD protein_NN ._. After_IN
          thirty-minutes_JJ of_IN incubation_NN with_IN 5_CD -_: HT_NNP (_( 10_CD -_: 9_CD -_: 10_CD -_: 5_CD M_NNP )_) ,_,
          there_EX was_VBD no_DT enhanced_JJ phosphorylation_NN of_IN p_NN 38_CD (_( figure_NN 2_CD ,_,
          bottom_NN )_) ._. In_IN contrast_NN ,_, incubation_NN with_IN anisomycin_NN (_( 500_CD
          ng_NN /_NN ml_NN )_) induced_VBN significant_JJ phosphorylation_NN of_IN p_NN 38_CD (_( 2_CD -_: fold_VB
          above_IN basal_NN )_) ._. These_DT data_NNS suggest_VBP that_IN 5_CD -_: HT_NNP does_VBZ not_RB
          activate_VBP the_DT p_NN 38_CD pathway_NN in_IN rat_NN vascular_NN smooth_JJ muscle_NN
          cells_NNS despite_IN the_DT ability_NN of_IN other_JJ agonists_NNS to_TO activate_VBP
          the_DT pathway_NN in_IN these_DT cells_NNS ._.
        
        
          The_DT JNK_NNP pathway_NN
          Figure_NN 3_CD shows_VBZ that_IN thirty_CD minutes_NNS of_IN incubation_NN with_IN
          5_CD -_: HT_NNP (_( 10_CD -_: 9_CD -_: 10_CD -_: 5_CD M_NNP )_) resulted_VBD in_IN a_DT trend_NN towards_IN a_DT modest_JJ
          increase_NN in_IN phosphorylation_NN of_IN the_DT p_NN 46_CD JNK_NNP isoform_NN ._. This_DT
          trend_NN ,_, however_RB ,_, was_VBD not_RB statistically_RB significant_JJ ._. In_IN
          contrast_NN ,_, anisomycin_NN (_( 500_CD ng_NN /_NN ml_NN )_) induced_VBN significant_JJ
          phosphorylation_NN of_IN the_DT p_NN 46_CD JNK_NNP isoform_NN (_( 5_CD -_: 7_CD fold_VB above_IN
          basal_NN )_) ._. Both_DT the_DT p_NN 54_CD and_CC p_NN 46_CD bands_NNS were_VBD analyzed_VBN by_IN
          densitometry_NN (_( data_NNS for_IN p_NN 54_CD not_RB shown_VBN )_) ._. However_RB ,_,
          incubation_NN with_IN 5_CD -_: HT_NNP did_VBD not_RB produce_VB statistically_RB
          significant_JJ activation_NN in_IN either_DT band_NN when_WRB compared_VBN to_TO
          vehicle_NN ._. These_DT data_NNS suggest_VBP that_IN 5_CD -_: HT_NNP does_VBZ not_RB
          substantially_RB activate_VBP the_DT JNK_NNP pathway_NN in_IN vascular_NN smooth_JJ
          muscle_NN cells_NNS ._. However_RB ,_, the_DT data_NNS obtained_VBN with_IN anisomycin_NN
          provides_VBZ evidence_NN that_IN this_DT pathway_NN can_MD be_VB activated_VBN in_IN
          these_DT cells_NNS ._.
          To_TO confirm_VB that_IN thirty_CD minutes_NNS was_VBD an_DT optimal_NN time_NN
          point_NN for_IN observing_VBG 5_CD -_: HT-induced_NNP phosphorylation_NN of_IN JNK_NNP ,_,
          we_PRP next_RB performed_VBD a_DT time_NN course_NN of_IN JNK_NNP phosphorylation_NN
          after_IN exposure_NN to_TO 5_CD -_: HT_NNP in_IN rat_NN vascular_NN smooth_JJ muscle_NN
          cells_NNS ._. At_IN no_DT time_NN point_NN (_( 5_CD min_NN ,_, 15_CD min_NN ,_, 30_CD min_NN and_CC 60_CD
          min_NN )_) did_VBD 5_CD -_: HT_NNP (_( 10_CD -_: 5_CD M_NNP )_) enhance_VB JNK_NNP phosphorylation_NN above_IN
          basal_NN levels_NNS (_( figure_NN 4_LS )_) ._. These_DT data_NNS fail_VBP to_TO support_VB a_DT
          role_NN for_IN 5_CD -_: HT-induced_NNP activation_NN of_IN the_DT JNK_NNP pathway_NN in_IN
          vascular_NN smooth_JJ muscle_NN cells_NNS ._.
          To_TO demonstrate_VB that_IN a_DT G-_NNP protein_NN coupled_VBN receptor_NN
          agonist_NN could_MD activate_VBP the_DT JNK_NNP pathway_NN in_IN our_PRP$ vascular_NN
          smooth_JJ muscle_NN cells_NNS ,_, we_PRP incubated_JJ the_DT cells_NNS with_IN
          angiotensin_NN II_NNP (_( 10_CD -_: 9_CD -_: 10_CD -_: 5_CD M_NNP )_) for_IN thirty_CD minutes_NNS ._.
          Angiotensin_NNP II_NNP (_( 10_CD -_: 8_CD -_: 10_CD -_: 5_CD M_NNP )_) produced_VBD a_DT significant_JJ
          increase_NN in_IN the_DT level_NN of_IN JNK_NNP phosphorylation_NN (_( figure_NN 5_LS )_) ._.
          The_DT authors_NNS speculate_VBP that_IN the_DT differences_NNS in_IN the_DT level_NN
          of_IN phosphorylation_NN of_IN the_DT p_NN 46_CD JNK_NNP isoform_NN in_IN the_DT vehicle_NN
          treatment_NN group_NN maybe_RB due_JJ to_TO differences_NNS in_IN the_DT JNK_NNP
          expression_NN over_IN time_NN in_IN cultured_JJ cells_NNS ._. The_DT cells_NNS used_VBN in_IN
          these_DT experiments_NNS were_VBD of_IN a_DT later_JJ passage_NN than_IN those_DT used_VBN
          for_IN the_DT 5_CD -_: HT_NNP incubation_NN studies_NNS ._. These_DT data_NNS ,_, in_IN addition_NN
          to_TO that_DT obtained_VBD with_IN anisomycin_NN ,_, demonstrate_VB that_IN in_IN
          these_DT vascular_NN smooth_JJ muscle_NN cells_NNS the_DT JNK_NNP pathway_NN can_MD be_VB
          activated_VBN ._.
          Due_JJ to_TO the_DT trend_NN toward_IN increased_VBN phosphorylation_NN of_IN
          both_DT the_DT p_NN 46_CD and_CC p_NN 54_CD JNK_NNP isoforms_NNS by_IN 5_CD -_: HT_NNP ,_, we_PRP next_RB
          performed_VBN JNK_NNP activity_NN assays_NNS to_TO determine_VB whether_IN 5_CD -_: HT_NNP
          had_VBD any_DT significant_JJ effect_NN on_IN kinase_NN activity_NN ._. This_DT assay_NN
          was_VBD chosen_VBN to_TO ensure_VB that_IN the_DT western_JJ analyses_NNS used_VBN were_VBD
          sufficiently_RB sensitive_JJ to_TO detect_VB changes_NNS in_IN the_DT
          activation_NN of_IN the_DT JNK_NNP pathway_NN ._. There_EX was_VBD no_DT significant_JJ
          difference_NN in_IN the_DT levels_NNS of_IN activity_NN at_IN any_DT concentration_NN
          of_IN 5_CD -_: HT_NNP (_( 10_CD -_: 9_CD -_: 10_CD -_: 5_CD M_NNP )_) after_IN thirty_CD minutes_NNS of_IN
          incubation_NN in_IN vascular_NN smooth_JJ muscle_NN cells_NNS (_( figure_NN 6_CD )_) ._. In_IN
          contrast_NN ,_, anisomycin_NN (_( 500_CD ng_NN /_NN ml_NN ,_, 30_CD min_NN )_) produced_VBD a_DT
          significant_JJ increase_NN in_IN JNK_NNP activation_NN (_( approximately_RB
          2_CD -_: fold_VB above_IN basal_NN )_) ._. These_DT data_NNS ,_, in_IN combination_NN with_IN the_DT
          above_JJ findings_NNS ,_, do_VBP not_RB support_VB a_DT role_NN for_IN 5_CD -_: HT_NNP in_IN the_DT
          activation_NN of_IN the_DT JNK_NNP pathway_NN in_IN vascular_NN smooth_JJ muscle_NN
          cells_NNS ._.
        
      
      
        Conclusions_NNP
        5_LS -_: HT_NNP is_VBZ an_DT activator_NN of_IN the_DT ERK_NNP pathway_NN in_IN vascular_NN
        smooth_JJ muscle_NN cells_NNS ._. In_IN contrast_NN ,_, 5_CD -_: HT_NNP appears_VBZ to_TO be_VB unable_JJ
        to_TO activate_VBP the_DT JNK_NNP and_CC p_NN 38_CD pathways_NNS in_IN vascular_NN smooth_JJ
        muscle_NN cells_NNS ._. No_DT observable_JJ changes_NNS in_IN activation_NN ,_, as_IN
        measured_VBN by_IN phosphorylation_NN status_NN ,_, were_VBD seen_VBN at_IN any_DT of_IN the_DT
        5_CD -_: HT_NNP concentrations_NNS (_( 10_CD -_: 9_CD -_: 10_CD -_: 5_CD M_NNP )_) or_CC time_NN points_NNS (_( 5_CD min_NN ,_,
        30_CD min_NN ,_, 60_CD min_NN and_CC 2_CD hr_NN )_) examined_VBD ._. The_DT data_NNS from_IN the_DT kinase_NN
        activity_NN assay_NN also_RB demonstrated_VBD no_DT activation_NN of_IN the_DT JNK_NNP
        pathway_NN by_IN 5_CD -_: HT_NNP ._.
        The_DT mitogen-activated_JJ protein_NN kinase_NN family_NN is_VBZ
        associated_VBN with_IN many_JJ cellular_JJ functions_NNS ._. The_DT ability_NN of_IN
        5_CD -_: HT_NNP to_TO activate_VBP the_DT ERK_NNP pathway_NN is_VBZ consistent_JJ with_IN 5_CD -_: HT_NNP 's_POS
        role_NN as_IN a_DT mitogenic_JJ stimulus_NN and_CC vasoconstrictor_NN ._. Several_JJ
        vasoactive_JJ G-_NNP protein_NN coupled_VBN agonists_NNS ,_, including_VBG
        angiotensin_NN II_NNP and_CC endothelin_NN ,_, have_VBP also_RB been_VBN shown_VBN to_TO
        activate_VBP the_DT ERK_NNP pathway_NN in_IN vascular_NN smooth_JJ muscle_NN cells_NNS [_NN
        6_CD 21_CD ]_NN ._. These_DT same_JJ hormones_NNS also_RB activate_VBP the_DT JNK_NNP and_CC p_NN 38_CD
        pathways_NNS ._. These_DT agonists_NNS have_VBP different_JJ time_NN course_NN and_CC
        concentration_NN profiles_NNS for_IN activation_NN of_IN the_DT different_JJ MAPK_NNP
        pathways_NNS ._. ERK_NNP activation_NN by_IN angiotensin_NN II_NNP and_CC 5_CD -_: HT_NNP occurs_VBZ
        at_IN relatively_RB lower_JJR agonist_NN concentrations_NNS and_CC within_IN five_CD
        minutes_NNS of_IN stimulation_NN (_( 19_CD ,_, 23_CD )_) ._. The_DT activation_NN of_IN p_NN 38_CD and_CC
        JNK_NNP pathways_NNS by_IN angiotensin_NN II_NNP and_CC endothelin_NN occurs_VBZ at_IN
        higher_JJR concentrations_NNS of_IN agonist_NN and_CC requires_VBZ a_DT longer_JJR
        incubation_NN with_IN the_DT stimulus_NN [_NN 18_CD 19_CD 25_CD ]_NN ._. There_EX are_VBP data_NNS
        which_WDT also_RB suggest_VBP that_IN different_JJ signal_NN transduction_NN
        pathways_NNS are_VBP utilized_JJ for_IN the_DT different_JJ pathways_NNS [_NN 25_CD 26_CD 27_CD
        ]_NN ._. This_DT differential_NN activation_NN of_IN MAPK_NNP pathways_NNS is_VBZ most_RBS
        likely_JJ due_NN to_TO the_DT role_NN that_IN each_DT plays_VBZ in_IN the_DT cell_NN ._. The_DT ERK_NNP
        pathway_NN is_VBZ associated_VBN with_IN growth_NN where_WRB as_IN the_DT p_NN 38_CD and_CC JNK_NNP
        pathways_NNS are_VBP "_'' stress_NN response_NN "_'' pathways_NNS ._.
        In_IN light_NN of_IN data_NNS for_IN the_DT other_JJ G-_NNP protein_NN coupled_VBN
        receptor_NN agonists_NNS ,_, the_DT inability_NN of_IN 5_CD -_: HT_NNP ,_, also_RB G-_NNP protein_NN
        coupled_VBN receptor_NN ,_, was_VBD initially_RB surprising_JJ ._. While_IN 5_CD -_: HT_NNP has_VBZ
        never_RB been_VBN shown_VBN to_TO increase_VB activation_NN of_IN either_DT the_DT p_NN 38_CD
        or_CC JNK_NNP pathways_NNS ,_, it_PRP has_VBZ been_VBN linked_VBN to_TO ERK_NNP activation_NN ._. The_DT
        5_CD -_: HT_NNP 
        2_CD A_DT receptor_NN is_VBZ the_DT primary_JJ serotonergic_JJ
        receptor_NN which_WDT couples_NNS to_TO activation_NN the_DT ERK_NNP pathway_NN in_IN
        vascular_NN smooth_JJ muscle_NN cells_NNS [_NN 28_CD ]_NN ._. 5_CD -_: HT_NNP 's_POS inability_NN to_TO
        activate_VBP the_DT JNK_NNP and_CC p_NN 38_CD pathways_NNS may_MD be_VB due_JJ to_TO a_DT lack_NN of_IN
        coupling_NN of_IN the_DT 5_CD -_: HT_NNP 
        2_CD A_DT receptor_NN signaling_VBG pathway_NN to_TO the_DT
        components_NNS in_IN the_DT JNK_NNP and_CC p_NN 38_CD pathways_NNS ._.
        It_PRP has_VBZ recently_RB been_VBN suggested_VBN that_IN G-_NNP protein_NN coupled_VBN
        receptors_NNS with_IN PDZ_NNP domains_NNS ,_, SH_NNP 2_CD -_: containing_VBG domains_NNS and_CC PTB_NNP
        domains_NNS participate_VBP in_IN protein-protein_JJ interactions_NNS with_IN
        partners_NNS other_JJ than_IN G-_NNP proteins_NNS ,_, such_JJ as_IN Grb_NNP 2_CD and_CC JAK_NNP 2_CD ,_,
        which_WDT may_MD allow_VB these_DT receptors_NNS to_TO bypass_VB the_DT G-_NNP proteins_NNS
        and_CC utilize_VB other_JJ signaling_VBG cascades_NNS (_( 29_CD )_) ._. This_DT ability_NN of_IN
        G-_NNP protein_NN coupled_VBN receptors_NNS to_TO modulate_VBP the_DT signal_NN cascade_NN
        used_VBD ,_, independent_JJ of_IN G-_NNP proteins_NNS ,_, suggests_VBZ a_DT broader_JJR range_NN
        of_IN interaction_NN with_IN signaling_VBG components_NNS ._. This_DT may_MD provide_VB
        one_CD explanation_NN for_IN the_DT 5_CD -_: HT_NNP activation_NN of_IN the_DT ERK_NNP and_CC its_PRP$
        lack_NN of_IN effect_NN on_IN the_DT JNK_NNP and_CC p_NN 38_CD pathways_NNS ._.
        Another_DT possible_JJ explanation_NN for_IN the_DT differential_NN
        activation_NN of_IN the_DT MAPK_NNP pathways_NNS by_IN 5_CD -_: HT_NNP may_MD relate_VB to_TO the_DT
        varied_VBD roles_NNS 5_CD -_: HT_NNP in_IN different_JJ cell_NN types_NNS and_CC the_DT multiple_JJ
        receptors_NNS which_WDT mediate_VB these_DT roles_NNS ._. When_WRB examining_VBG the_DT
        physiological_JJ role_NN of_IN 5_CD -_: HT_NNP in_IN other_JJ cell_NN types_NNS ,_, in_IN regards_VBZ
        to_TO apoptosis_NNS and_CC cellular_JJ responses_NNS to_TO stress_VB ,_, 5_CD -_: HT_NNP is_VBZ
        generally_RB anti-apoptotic_JJ [_NN 30_CD 31_CD 32_CD ]_NN ._. In_IN particular_JJ ,_, in_IN
        neuronal_NN cells_NNS the_DT 5_CD -_: HT_NNP 
        1_CD A_DT receptor_NN is_VBZ upregulated_JJ under_IN
        conditions_NNS of_IN cellular_JJ stress_NN and_CC is_VBZ anti-apoptotic_JJ [_NN 33_CD 34_CD
        ]_NN ._. The_DT anti-apoptotic_JJ effects_NNS of_IN 5_CD -_: HT_NNP maybe_RB due_JJ to_TO
        scavenging_VBG of_IN reactive_JJ oxygen_NN species_NNS [_NN 35_CD ]_NN as_RB well_RB as_IN
        stimulation_NN of_IN the_DT ERK_NNP pathway_NN which_WDT results_NNS in_IN inhibition_NN
        of_IN a_DT caspase-_NN 3_CD -_: like_IN enzyme_NN [_NN 32_CD ]_NN ._. There_EX are_VBP no_DT currently_RB
        published_VBN studies_NNS examining_VBG the_DT role_NN of_IN 5_CD -_: HT_NNP as_IN an_DT
        anti-apoptotic_JJ factor_NN in_IN vascular_NN smooth_JJ muscle_NN cells_NNS ._. It_PRP
        may_MD be_VB that_IN under_IN stressful_JJ conditions_NNS ,_, such_JJ as_IN a_DT disease_NN
        state_NN or_CC a_DT loss_NN of_IN nutrients_NNS which_WDT occurs_VBZ in_IN a_DT state_NN of_IN
        ischemia_NN ,_, the_DT smooth_JJ muscle_NN cells_NNS upregulate_NN a_DT new_JJ
        complement_VB of_IN 5_CD -_: HT_NNP receptors_NNS [_NN 33_CD 34_CD 35_CD ]_NN ._. These_DT new_JJ
        receptors_NNS maybe_RB involved_VBN in_IN activation_NN of_IN the_DT ERK_NNP ,_, p_NN 38_CD and_CC
        JNK_NNP pathways_NNS ,_, but_CC the_DT studies_NNS presented_VBN here_RB do_VBP not_RB
        directly_RB address_VB this_DT issue_NN ._. They_PRP do_VBP ,_, however_RB ,_, support_NN the_DT
        conclusion_NN that_IN the_DT 5_CD -_: HT_NNP 
        2_CD A_DT receptor_NN does_VBZ not_RB activate_VBP the_DT p_NN 38_CD
        orJNK_NN pathways_NNS in_IN rat_NN vascular_NN smooth_JJ muscle_NN cells_NNS ._.
      
      
        Methods_NNP
        
          Aortic_NNP smooth_JJ muscle_NN cell_NN culture_NN
          Vascular_NNP smooth_JJ muscle_NN cells_NNS were_VBD derived_VBN from_IN the_DT
          aorta_NN of_IN male_JJ Sprague-_NNP Dawley_NNP rats_NNS by_IN an_DT explant_NN method_NN
          previously_RB described_VBD [_NN 36_CD ]_NN ._. The_DT smooth_JJ muscle_NN cells_NNS
          were_VBD plated_JJ on_IN to_TO P-_NNP 100_CD 's_POS and_CC grown_VBN to_TO confluence_NN ._. The_DT
          cells_NNS were_VBD used_VBN between_IN passages_NNS 2_CD and_CC 9_CD ._. The_DT cells_NNS were_VBD
          positively_RB stained_JJ for_IN smooth_JJ muscle_NN α-actin_JJ (_( Oncogene_NNP
          Research_NNP Products_NNPS ,_, Boston_NNP ,_, MA_NNP ;_: Fluorescein_NNP labeled_VBD goat_NN
          anti-mouse_JJ secondary_JJ antibody_NN ,_, Molecular_NNP Probes_NNP ,_, Eugene_NNP ,_,
          OR_NNP )_) with_IN each_DT new_JJ isolation_NN ._.
        
        
          Aortic_NNP smooth_JJ muscle_NN cells_NNS experiments_NNS
          Cells_NNP (_( P-_NNP 100_CD plates_NNS )_) were_VBD switched_VBN to_TO physiological_JJ
          salt_NN solution_NN (_( 4_CD ml_NN )_) [_NN consisting_VBG of_IN (_( in_IN mmol_NN /_NN L_NNP )_) NaCI_NNP ,_,
          103_CD ;_: KCI_NNP ,_, 4_CD ._. 7_CD ;_: KH_NNP 
          2_CD PO_NNP 
          4_CD ,_, 1_CD ._. 18_CD ;_: MgSO_NNP 
          4_CD •_NN 7_CD H_NNP 
          2_CD O_NNP ,_, 1_CD ._. 17_CD ;_: CaCl_NNP 
          2_CD •_NN 2_CD H_NNP 
          2_CD O_NNP ,_, 1_CD ._. 6_CD ;_: NaHCO_NNP 
          3_CD ,_, 14_CD ._. 9_CD ;_: dextrose_NN ,_, 5_CD ._. 5_CD ;_: and_CC CaNa_NNP 
          2_CD EDTA_NNP ,_, 0_CD ._. 03_CD ]_NN for_IN one_CD hour_NN prior_RB to_TO
          addition_NN of_IN agonist_NN ._. At_IN this_DT time_NN ,_, okadaic_JJ acid_NN (_( 1_CD μM_NN )_) ,_,
          sodium_NN orthovanadate_NN (_( 1_CD μM_NN )_) and_CC PD_NNP 098059_CD (_( 10_CD μM_NN )_) or_CC
          vehicle_NN (_( 0_CD ._. 1_LS -_: ._. 5_LS %_NN DMSO_NNP )_) was_VBD added_VBN and_CC allowed_VBN to_TO
          equilibrate_NN for_IN one_CD hour_NN ._. PD_NNP 098059_CD ,_, an_DT inhibitor_NN of_IN MEK_NNP
          activation_NN ,_, was_VBD included_VBN in_IN all_DT experiments_NNS ,_, except_IN the_DT
          ERK_NNP activation_NN experiments_NNS ,_, to_TO increase_VB the_DT specificity_NN
          of_IN the_DT phospho-_NN JNK_NNP antibody_NN which_WDT recognizes_VBZ the_DT 44_CD and_CC
          42_CD kDa_NN ERK_NNP bands_NNS as_RB well_RB as_IN bands_NNS at_IN 54_CD and_CC 46_CD kDa_NN ._. In_IN
          the_DT presence_NN of_IN PD_NNP 098059_CD ,_, the_DT bands_NNS at_IN 42_CD and_CC 44_CD kDa_NN were_VBD
          significantly_RB reduced_VBN ._. Each_DT dish_NN was_VBD incubated_JJ with_IN one_CD
          agonist_NN concentration_NN [_NN 5_CD -_: HT_NNP (_( 10_CD -_: 9_CD -_: 10_CD -_: 5_CD M_NNP )_) ,_, angiotensin_NN
          II_NNP (_( 10_CD -_: 9_CD -_: 10_CD -_: 5_CD M_NNP )_) or_CC anisomycin_NN (_( 500_CD ng_NN /_NN ml_NN [_NN 37_CD ]_NN )_) ]_NN for_IN
          thirty_CD minutes_NNS ._. Plates_NNP were_VBD placed_VBN on_IN ice_NN and_CC incubation_NN
          buffer_NN aspirated_JJ ._. Plates_NNP were_VBD washed_VBN with_IN ice-cold_JJ
          phosphate-buffered_JJ saline_NN containing_VBG sodium_NN orthovanadate_NN
          as_IN a_DT tyrosine_NN phosphatase_NN inhibitor_NN (_( 10_CD mM_NN sodium_NN
          phosphate_NN ,_, 150_CD mM_NN NaCI_NNP ,_, 1_CD mM_NN Na_NNP 
          3_CD VO_NNP 
          4_CD ,_, pH_NN 7_CD ._. 0_CD )_) ._. Five_CD hundred_CD microliters_NNS
          of_IN supplemented_JJ RIPA_NNP lysis_NNS buffer_NN (_( 50_CD mM_NN Tris-_NNP HCI_NNP pH_NN 7_CD ._. 5_CD ,_,
          150_CD mM_NN NaCI_NNP ,_, 2_CD mM_NN EGTA_NNP ,_, 0_CD ._. 1_CD %_NN Triton_NNP X-_NNP 100_CD ,_, 1_CD mM_NN PMSF_NNP ,_, 10_CD
          ug_NN /_NN ml_NN aprotinin_NN ,_, 10_CD ug_NN /_NN ml_NN leupeptin_NN ,_, 1_CD mM_NN sodium_NN
          orthovanadate_NN )_) were_VBD added_VBN to_TO each_DT dish_NN and_CC cells_NNS were_VBD
          harvested_VBN with_IN a_DT rubber_NN policeman_NN ._. Lysates_NNP were_VBD
          centrifuged_JJ at_IN 14_CD ,_, 000_CD g_SYM for_IN 10_CD minutes_NNS at_IN 4_CD °_NN C_NNP ._. Protein_NNP
          concentrations_NNS of_IN the_DT resulting_VBG supernatant_NN were_VBD measured_VBN
          using_VBG the_DT BSA_NNP method_NN (_( Bio-_NNP Rad_NNP ,_, Hercules_NNP ,_, CA_NNP )_) ._. The_DT gels_NNS
          were_VBD also_RB stained_JJ with_IN Gel_NNP Code_NNP Blue_NNP ®_NN (_( Pierce_NNP ,_, Rockford_NNP ,_,
          IL_NNP )_) to_TO validate_NN equal_JJ loading_NN of_IN protein_NN ._.
        
        
          Immunoblotting_NNP protocol_NN
          Supernatant_NNP (_( 4_CD :_: 1_CD in_IN denaturing_VBG loading_NN buffer_NN ,_, boiled_VBD
          5_CD minutes_NNS )_) was_VBD loaded_VBN ,_, separated_JJ on_IN 10_CD %_NN denaturing_VBG
          SDS-polyacrylamide_NNP gels_NNS ,_, and_CC transferred_VBD to_TO Immobilon-_NNP P_NN
          membranes_NNS ._. Membranes_NNP were_VBD blocked_VBN for_IN 3_CD -_: 4_CD hours_NNS in_IN Tris_NNP
          buffer_NN saline_NN +_NN Tween-_NNP 20_CD (_( 0_CD ._. 1_LS %_NN ;_: TBS-T_NNP )_) containing_VBG 4_CD %_NN
          chick_NN egg_NN ovalbulmin_NN and_CC 0_CD ._. 025_CD %_NN sodium_NN azide_NN ._. Rabbit_NNP
          anti-phospho_JJ Erk_NNP MAPK_NNP (_( 1_CD :_: 5000_CD ,_, Promega_NNP ,_, Madison_NNP ,_, Wl_NNP )_) ,_,
          rabbit_NN anti-phospho_JJ JNK_NNP MAPK_NNP (_( 1_CD :_: 5000_CD ,_, Promega_NNP ,_, Madison_NNP
          Wl_NNP )_) ,_, rabbit_NN anti-phospho_JJ p_NN 38_CD MAPK_NNP (_( 1_CD :_: 1000_CD ,_, Cell_NNP
          Signaling_NNP ,_, Beverly_NNP ,_, MA_NNP )_) ,_, mouse_NN anti-total_JJ Erk_NNP (_( 1_CD :_: 5000_CD ,_,
          Zymed_NNP ,_, San_NNP Francisco_NNP ,_, CA_NNP )_) rabbit_NN anti-total_JJ JNK_NNP MAPK_NNP
          (_( 1_CD :_: 5000_CD ,_, Santa_NNP Cruz_NNP BioTechnologies_NNP ,_, Santa_NNP Cruz_NNP ,_, CA_NNP )_) or_CC
          rabbit_NN anti-total_JJ p_NN 38_CD MAPK_NNP (_( 1_CD :_: 1000_CD ,_, Cell_NNP Signaling_NNP ,_,
          Beverly_NNP ,_, MA_NNP )_) were_VBD incubated_JJ with_IN blots_NNS overnight_JJ (_( 4_CD °_NN C_NNP )_) ._.
          Following_VBG washes_NNS ,_, secondary_JJ antibody_NN linked_VBN to_TO
          horseradish_NN peroxidase_NN [_NN anti-rabbit_JJ (_( 1_CD :_: 2000_CD ,_, Zymed_NNP
          Laboratories_NNPS ,_, S_NNP ._. San_NNP Francisco_NNP ,_, CA_NNP )_) or_CC anti-mouse_JJ
          (_( 1_CD :_: 7500_CD ,_, Amersham_NNP ,_, Arlington_NNP Heights_NNP IL_NNP )_) ]_NN was_VBD added_VBN for_IN
          one_CD hour_NN and_CC incubated_JJ with_IN blots_NNS at_IN 4_CD °_NN C_NNP ._. Enhanced_NNP
          chemiluminescence_NN was_VBD performed_VBN using_VBG standard_JJ reagents_NNS
          (_( Amersham_NNP Laboratories_NNPS ,_, Arlington_NNP Heights_NNP ,_, IL_NNP )_) ._.
        
        
          Kinase_NNP activity_NN assay_NN protocol_NN
          Primary_JJ vascular_NN smooth_JJ muscle_NN cell_NN preparations_NNS were_VBD
          treated_VBN with_IN agonists_NNS as_IN described_VBN above_IN ._. They_PRP were_VBD then_RB
          lysed_JJ in_IN a_DT protein_NN kinase_NN lysis_NNS buffer_NN [_NN 50_CD mM_NN HEPES_NNP ,_, pH_NN
          7_CD ._. 5_CD ,_, 150_CD mM_NN NaCI_NNP ,_, 1_CD ._. 5_CD mM_NN MgCI_NNP 2_CD ,_, 1_CD mM_NN EGTA_NNP ,_, 1_CD mM_NN sodium_NN
          vanadate_NN ,_, 50_CD mM_NN sodium_NN fluoride_NN ,_, 20_CD mM_NN
          beta-glycerophosphate_JJ ,_, 10_CD %_NN (_( vol_NN /_NN vol_NN )_) glycerol_NN ,_, 1_CD %_NN
          (_( vol_NN /_NN vol_NN )_) Triton_NNP X-_NNP 100_CD ,_, and_CC protease_NN inhibitors_NNS (_( 1_CD mM_NN
          PMSF_NNP ,_, 1_CD ug_NN /_NN ml_NN pepstatin_NN A_DT 1_CD ,_, 1_CD ug_NN /_NN ml_NN leupeptin_NN ,_, and_CC 1_CD
          ug_NN /_NN ml_NN aprotinin_NN ]_NN ._. Equal_NNP protein_NN amounts_NNS of_IN each_DT cell_NN
          lysate_NN (_( usually_RB 100_CD ug_NN )_) were_VBD incubated_JJ for_IN 3_CD h_NN at_IN 4_CD °_NN C_NNP in_IN
          the_DT presence_NN of_IN purified_JJ GST-c-Jun-_NNP (_( 1_CD -_: 79_CD )_) bound_VBN to_TO
          glutathione-agarose_JJ beads_NNS (_( 2_CD ._. 8_CD ug_NN GST-c-Jun_NNP /_NN ul_NN beads_NNS )_) as_RB
          previously_RB described_VBD [_NN 38_CD ]_NN ._. Beads_NNP were_VBD washed_VBN 2_CD times_NNS
          with_IN HNTG_NNP buffer_NN (_( HEPES_NNP 20_CD mM_NN pH_NN 7_CD ._. 5_LS ,_, NaCI_NNP 150_CD mM_NN ,_, Triton_NNP
          X-_NNP 100_CD 0_CD ._. 10_CD %_NN ,_, glycerol_NN 10_CD %_NN )_) followed_VBN by_IN an_DT additional_JJ
          washing_NN with_IN HNTG_NNP buffer_NN +_NN 1_CD %_NN bovine_JJ serum_NN albumin_NN (_( BSA_NNP )_) ._.
          Samples_NNP were_VBD then_RB centrifuged_JJ at_IN 13_CD ,_, 000_CD rpm_NN for_IN 2_CD min_NN and_CC
          the_DT supernatant_NN was_VBD discarded_VBN ._. The_DT pellets_NNS were_VBD washed_VBN 2_CD
          times_NNS with_IN HNTG_NNP buffer_NN and_CC 2_CD times_NNS with_IN JKAW_NNP buffer_NN
          (_( HEPES_NNP 25_CD mM_NN ,_, glycerol_NN 10_CD %_NN ,_, MgCl_NNP 
          2_CD 20_CD mM_NN ,_, Na_NNP 
          3_CD VO_NNP 
          4_CD 0_CD ._. 1_CD mM_NN ,_, beta-glycerophosphate_JJ 12_CD ._. 5_LS
          mM_NN ,_, EGTA_NNP 0_CD ._. 5_CD mM_NN ,_, NaF_NNP 0_CD ._. 5_CD mM_NN )_) ._. The_DT pellets_NNS were_VBD then_RB
          resuspended_JJ in_IN 50_CD ._. 5_LS μl_NN JKAW_NNP reaction_NN buffer_NN containing_VBG 20_CD
          μCi_NN [_NN -_: 32_CD P_NN ]_NN ATP_NNP and_CC 50_CD μM_NN unlabeled_JJ ATP_NNP ._. After_IN 30_CD min_NN at_IN
          37_CD °_NN C_NNP ,_, reactions_NNS were_VBD terminated_VBN by_IN the_DT addition_NN of_IN 8_CD ul_NN
          SDS_NNP loading_NN buffer_NN ,_, samples_NNS were_VBD boiled_VBD and_CC separated_VBN by_IN
          SDS-PAGE_NNP ._. Proteins_NNPS were_VBD transferred_VBN to_TO stabilized_VBN
          nitrocellulose_NN membranes_NNS and_CC the_DT bands_NNS corresponding_JJ to_TO
          phosporylated_JJ c-_NN Jun_NNP were_VBD counted_VBN by_IN a_DT phosphorimager_NN
          (_( Storm_NN model_NN 860_CD ,_, Molecular_NNP Dynamics_NNP ,_, Sunnyvale_NNP CA_NNP )_) ._.
        
        
          Data_NNP analysis_NN
          Cell_NNP experiments_NNS were_VBD performed_VBN three_CD or_CC four_CD times_NNS
          with_IN each_DT repetition_NN of_IN the_DT experiment_NN being_VBG performed_VBN in_IN
          cells_NNS from_IN explants_NNS derived_VBN from_IN different_JJ animals_NNS ._. Thus_RB ,_,
          experiments_NNS are_VBP representative_NN of_IN responses_NNS of_IN 3_CD or_CC 4_CD
          different_JJ animals_NNS ._. Unpaired_NNP Student_NNP 's_POS t_NN tests_NNS were_VBD used_VBN
          where_WRB appropriate_JJ in_IN comparing_VBG two_CD group_NN responses_NNS and_CC a_DT
          one_CD way_NN ANOVA_NNP test_NN was_VBD used_VBN when_WRB comparing_VBG responses_NNS of_IN
          three_CD or_CC more_JJR groups_NNS (_( p_NN <_NN 0_CD ._. 05_CD considered_VBN
          statistically_RB significant_JJ )_) ._. Phosphorimager_NNP data_NNS was_VBD
          captured_VBN using_VBG Image_NN Quant_NN 5_CD ._. 1_CD software_NN (_( Molecular_NNP
          Dynamics_NNP ,_, SunnyVale_NNP ,_, CA_NNP )_) ._. Quantitation_NNP of_IN all_DT band_NN
          densities_NNS was_VBD performed_VBN using_VBG the_DT public_JJ domain_NN NIH_NNP Image_NN
          (_( v_NN ._. 1_LS ._. 62_CD )_) ._.
        
      
    
  
